01234nas a2200145   4500008004100000024000700041245002800048210002700076260001800103300001000121490000600131520086800137100001801005856006501023       2023                        eng d  a0300aDrug Review: Vonoprazan0 aDrug Review Vonoprazan  cDecember 2023  a71-720 v93 a<p class="rtejustify">Registrations: It had been registered in the following countries: United States of America (USA), United Kingdom (UK), Canada, and Saudi Arabia (SA.) USA, and Japan. Trade name (USA); VOQUEZNA Registration number (SA); Not available. Insurance Drug Formulary (SA); Not available. General Information: Registered Company: Pathom Pharmaceutics. Regulatory Status: RX. Mechanism of Action: Vonoprazan Potassium-competitive acid blocker (PCAB); inhibition in a potassiumcompetitive manner the H+, K+-ATPase enzyme system. Ampicillin derivative penicillin-binding proteins and cell wall inhibitor. Clarithromycin reversibly binds to the P site of 50S ribosomal subunit as macrolide antimicrobial; and inhibits RNA-dependent protein synthesis by stimulating the peptidyl t-RNA dissociation from ribosomes.&nbsp;<strong> Read more...</strong></p>
1 aAlsaab, Juman  uhttps://www.ptbreports.org/article/2023/9/3/105530ptb2023912